Browse > Article

Isoflavones Extracted from Sophorae fructus Upregulate IGF-1 and TGF-$\beta$ and Inhibit Osteoclastogenesis in Rat Born Marrow Cells  

Joo, Seong-Soo (Department of Immunology, College of Pharmacy, Chung-Ang University)
Won, Tae-Joon (Department of Immunology, College of Pharmacy, Chung-Ang University)
Kang, Hee-Cheol (Department of Immunology, College of Pharmacy, Chung-Ang University)
Lee, Do-Ik (Department of Immunology, College of Pharmacy, Chung-Ang University)
Publication Information
Archives of Pharmacal Research / v.27, no.1, 2004 , pp. 99-105 More about this Journal
Abstract
Isoflavones have been a central subject in research on the natural phytoestrogens found in Leguminosae. Their effects on bone formation and remodeling are important in that they can act like estrogen by binding on estrogen receptors on the target cell surface. We, therefore, believed that isoflavones may help in the treatment of patients with estrogen deficiency disease such as estrogen replacement therapy (ERT) for osteoporosis. As commonly known, osteoporosis is one of the hormonal deficiency diseases, especially in menopausal women. When estrogen is no longer produced in the body a remarkable bone remodeling process occurs, and the associated events are regulated by growth factors in the osteoblast lineage. In the present study, we investigated whether isoflavones (Isocal) extracted from Sophorae fructus affect the growth factors IGF-I and TGF-$\beta$ that have been known to be related with bone formation. In the study, we found that the active control (PIII) effectively enhanced the level of nitric oxide (NO) and growth factors, and thereby inhibited osteoclastogenesis. The most efficient concentration was $10^{-8}$% within five days, whereas the comparative control (soybean isoflavone) was not as effective even at a lower concentration. In conclusion, the products which contain enriched glucosidic isoflavone and nutrient supplements such as shark cartilage and calcium can be used for osteoporosis therapy by enhancing the production of IGF-I and TGF-$\beta$. Furthermore, the NO produced through endothelial constitutive NO synthase (ecNOS) may playa role in inhibiting bone reabsorption.
Keywords
Isoflavone; Sophorae fructus; Osteoclastogenesis; Growth factors; Nitric oxide;
Citations & Related Records

Times Cited By Web Of Science : 8  (Related Records In Web of Science)
Times Cited By SCOPUS : 9
연도 인용수 순위
1 Centrella, M., McCarthy, T., and Cannalis, E., Transforming growth factor-beta and remodeling of bone. J. Bone Joint Surg. Am., 73, 1418-1428 (1991)   DOI
2 Kanamaru, Y., Takada, T., Saura, R., and Mizuno. K., Effect of nitric oxide on mouse clonal osteogenic cell, MC3T3-E1, proliferation in vitro. Kobe J. Med. Sci., 47, 1-11 (2001)
3 Raisz, L. G., The osteoporosis revolution. Ann. Intern. Med., 126, 458-462 (1997)   DOI   PUBMED   ScienceOn
4 Wimalawansa, S. J., De Marco, G., Gangula, P., and Yallampalli, Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone, 18, 301-304 (1996)   DOI   ScienceOn
5 Joo, S. S., Chang, J. K., Park, J. H., Kang, H. C., and Lee, D. I., Immuno activation of lectin-conjugated praecoxin A on IL-6, IL-12 expression. Arch. Pharm. Res., 25, 954-963 (2002)   DOI   ScienceOn
6 Yamaguchi, M. and Gao, Y. H., Inhibitory effect of genistein on bone reabsorption in tissue culture. Biochem. Phamacol., 55, 71-76 (1998)   DOI   ScienceOn
7 Eastel, R., Treatment of postmenopausal osteoporosis. N. Engl. J. Med., 338, 736-746 (1998)   DOI   PUBMED   ScienceOn
8 Lian, J., Stein, G., Canalis, E., Robey, P., and Boskey, A., Bone formation: osteoblast lineage cells, growth factors, matrix proteins, and the mineralization process in. In Favus M, ed. Primer on the metabolic bone disease and disorders of mineral metabolism. Vol. 1. Philadelphia: Lippincott Williams and Wilkins (1999)
9 Brancli, M. L., Hukkanen, M., Umeda, T., Moradi-Bidhendi, N., Bianchi, S., Gross, S. S., Polak, J. M., and Macintyre, I. Bidirectional regulation of osteoclast function by nitric oxide synthesis isofors. Proc. Natl. Acad. Sci. USA, 92, 2954-2958 (1995)   DOI   ScienceOn
10 Mundy, G., Bone modeling. In: Favus M, ed. Primer on the metabolic bone disease and disorders of mineral metabolism. Vol. 1. 4th ed. Philadelphia, Lippincott Williams and Wilkins (1999)
11 van't Hof, R. J. and Ralston, S. H., Nitric oxide and bone. Immunology, 103, 255-261 (2001)   DOI   ScienceOn
12 Greenfield, E. M., Bi, Y., and Miyauchi, A., Regulation of osteoclast activity. Life Sicence, 65, 1087-1102 (1999)   DOI   ScienceOn
13 Klein-Nulend, J., Helfrich, M. H., Sterck, J. G., MacPherson, H., Joldersma, M., Raison, S. H., Semeins, C. M., and Burger, E. H, Nitric oxide response to shear stress by human bone cell culture is endothelial nitric oxide synthase dependant. Biochem. Biophys. Res. Commun., 250, 108-114 (1998)   DOI   ScienceOn
14 Bilezikian, J. P., Morishima, A., Bell, J., and Grumbach, M.M., Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N. Engl. J. Med., 339, 599-603 (1998)   DOI   ScienceOn
15 Amonkar, M. M. and Mody, R., Developing profiles of postmenopausal women being prescribed oestrogen therapy to prevent osteoporosis. J. community Health, 27, 335-350 (2002)   DOI   ScienceOn
16 Armpur, K. E. and Ralston, S. H., Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells. Endocrinology, 139, 799-802 (1998)   DOI   ScienceOn
17 Aubin, J. E. and Bonnelye, E., Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone reabsorption. Osteoporos. Int., 11, 905-913 (2000)   DOI   ScienceOn
18 Pacifici, R., Cytokines, estrogen and postmenopausal osteoporosis-the second decade. Endocrinology, 139, 2659-2661 (1998)   DOI   PUBMED   ScienceOn
19 Riggs, B. L., Khosia, S., and Melton, L. J., A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res., 13, 763-773 (1998)   DOI   ScienceOn
20 Aguirre, J., Buttery, L., O'Shaughnessy, M., Afzal, F., Fernandez de Marticorena, I., Hukkanen, M., Huang, P., Manlntyre, I., and Polak, J., Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am. J. Pathol., 158(1), 247-257 (2001)   DOI   ScienceOn
21 Setchell, K. D., Abstract presented at: Second international symposium on the role of soy in preventing and treating chronic disease. Brussel Belgium (1996)
22 Messina, M. and Messina, V., Soyfood, soybean isoflavone, abd bone health: a brief overview. J. Renal Nutrition, 10, 63-68 (2000)   DOI   ScienceOn
23 Baylink, D. J., Finkelman, R. D., and Moban, S., Growth factors to stimulate bone formation. J. Bone Miner. Res., 2(8), S565-S572 (1993)
24 Mundy, G. R., Bone remodeling and its disorders (ed. M. Dunits). London, UK (1995)
25 Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., and Higashio, K., RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun., 253, 395-400 (1998)   DOI   ScienceOn
26 Swolin-Eide, D. and Ohlsson, C., Effects of cortisol on the expression of interleukin-6 and interleukin-$1{\beta}$ in human osteoblast like cells. J. Endocrinology, 156, 107-114 (1998)   DOI   ScienceOn
27 Udagawa, N., Takahashi, N., Matsuzaki, K., Jimi, E., Tsurukai, T., Itoh, K., Nakagawa, H., Yasuda, H., Goto, M., Tsuda, E., Higashio, K., Martin, T. J., and Suda, T., Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone, 5, 517-523 (1999)
28 Duncan, A. M., Phipps, W. R., and Kurzer, M. S., Phyto-oestrogen. Best Practice & Research Clinical Endocrinology and Metabolism, 17, 253-271 (2003)   DOI   ScienceOn
29 Warren, M. P., Shortle, B., and Dominguez, J. E., Use of alternative therapies in menopause. Best Practice & Research Clinical Obstetrics and Gynaecology, 16(3), 411-448 (2002)   DOI   ScienceOn
30 Adlercreutz, H., Phyto-oestrogens and cancer. Lancet Oncology, 3, 364-373 (2002)   DOI   PUBMED   ScienceOn